RECURSION PHARMACEUTICALS, INC. Contract Liability (Deferred Revenue)
RECURSION PHARMACEUTICALS, INC. (RXRX) had Contract Liability (Deferred Revenue) of $27.59 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-05
- 2026-06-30: Contract with Customer, Liability, Current $27.59M.
- 2026-03-31: Contract with Customer, Liability, Current $32.79M.
- 2025-12-31: Contract with Customer, Liability, Current $37.60M.
- 2025-09-30: Contract with Customer, Liability, Current $47.36M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $27.59M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $32.79M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $37.60M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $47.36M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $39.69M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $39.65M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $61.77M 10-K · filed 2026-02-25 |
| 2024-09-30 | $49.58M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $32.20M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $36.62M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $36.43M 10-K · filed 2025-02-28 |
| 2023-09-30 | $44.00M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $73.11M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $57.76M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $56.73M 10-K · filed 2024-02-29 |
| 2022-09-30 | $46.75M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $63.78M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $54.25M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $10.00M 10-K · filed 2023-02-27 |
| 2021-09-30 | $10.00M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $10.00M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $10.00M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $10.00M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |